Trials / Completed
CompletedNCT02383212
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 398 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cemiplimab | |
| RADIATION | Hypofractionated radiotherapy | |
| DRUG | Cyclophosphamide | |
| DRUG | Docetaxel | |
| DRUG | Carboplatin | |
| DRUG | GM-CSF | |
| DRUG | Paclitaxel | |
| DRUG | Pemetrexed |
Timeline
- Start date
- 2015-02-02
- Primary completion
- 2019-11-18
- Completion
- 2019-11-18
- First posted
- 2015-03-09
- Last updated
- 2020-01-27
Locations
47 sites across 3 countries: United States, Australia, Spain
Source: ClinicalTrials.gov record NCT02383212. Inclusion in this directory is not an endorsement.